A Phase I Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers

Trial Profile

A Phase I Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs CYC 065 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Cyclacel Pharmaceuticals
  • Most Recent Events

    • 09 Aug 2017 According to a Cyclacel Pharmaceuticals media release, Part 2 will evaluate CYC065 in a more intensive schedule for 2 days per week, for 2 weeks of a three-week cycle.
    • 07 Aug 2017 According to a Cyclacel Pharmaceuticals media release, the recommended Phase 2 dose (RP2D) has been selected from part 1 of this trial, and part 2 of the study has been initiated aiming to enroll patients with advanced solid tumors, and in particular cyclin E amplified tumors.
    • 07 Aug 2017 Results from part 1 of the trial (n =24) published in a Cyclacel Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top